Clinical trial
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute…
NCT00016159 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00016159 |
|---|---|
| Title | Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia |
| Official title | Phase II Study Of Combined Modality Postremission Therapy As Determined By Molecular Response (Adaptive Regulation) In The Treatment Of Acute Promyelocytic Leukemia (APL) |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, lintuzumab, arsenic trioxide, idarubicin, tretinoin |
| Enrollment | 35 |
| Start date | Nov 1, 2000 |
| Primary completion | Mar 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: